BCL2 and acute myeloid leukemia: Interestingly, Hoffman-Luca et al. reported that Acute Myeloid Leukaemia (AML) cell lines that displayed resistance to MDM2 inhibitors retained sensitivity to BCL2 inhibitors [31], and Carter et al. reported the synergistic effects of an MDM2 BCL2 inhibitor combination in blast crisis Chronic Myeloid Leukaemia (CML) cells [32].